|
- Predicting Relapse After Alcohol Use Disorder Treatment in a High-Risk . . .
On average, two-thirds of individuals treated for alcohol use disorder (AUD) relapse within six months There is a critical need to identify modifiable risk factors associated with relapse that can be addressed during AUD treatment Candidate
- Time to relapse following treatment for methamphetamine use: a long . . .
Highest rates of relapse occurred early in the post-treatment period, with half the sample relapsing within six months This predominant early relapse emphasizes the need for further development of continuing care and strategies for connecting engaging MA users to abstinence-promoting resources immediately following SUD treatment (Dennis and
- Formulary Restrictions and Relapse Episodes in Persons With Relapsing . . .
This cohort study examines the association between formulary coverage for multiple sclerosis (MS) disease-modifying therapies and MS relapse among Medicare beneficiaries with stand-alone or Medicare Advantage prescription drug plans
- The magnitude of relapse after substance abuse and its influencing . . .
The relapse rate among rehabilitees three months or more after treatment was 129 (73 3 %) Among the 176 participants, 128 (73 6 %) reported receiving no post-treatment support from the community
- Factors Associated with Relapses in Alcohol and Substance Use Disorder
Alcohol and substance use disorder is a persistent illness characterized by remissions and relapses 5 Relapse rates are found to be similar across various substance addictions, with many people returning to substance use within the first 3 months following treatment and relapse rates of around 70% at 1 year following treatment 6, 7 One study
- Perceived Relapse Risk and Desire for Medication Assisted Treatment . . .
A quarter of our participants admitted to drug relapse on the day of their last detoxification discharge, and the majority relapsed within the first month Indeed, many reported being in a detox program within the month prior to study enrollment
- Association between duration of antidepressant treatment for major . . .
A single-group summary meta-analysis was performed to calculate 6-month relapse rates after discontinuation Meta-regression with restricted cubic splines was performed to model the non-linear relationship between treatment duration and relapse rate after discontinuation Thirty-five RCTs were included
- An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized . . .
In study 2, relapse rates were significantly lower for desvenlafaxine versus placebo at months 1, 2, and 3 for both definitions (P < 0001– 002) Hazard ratios were similar at months 1, 2, and 3 and overall for both studies (0 382–0 639) Conclusions: Desvenlafaxine 50 to 400 mg d effectively prevented relapse at 6 months
|
|
|